POKONZA

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name: POKONZA
Generic name: POTASSIUM CHLORIDE
Manufacturer: Carwin Pharmaceutical Associates, LLC
Product type: HUMAN PRESCRIPTION DRUG
SPL set ID: 0700c19e-abca-4527-8944-e4440a32e3af
SPL ID: 5e195343-8fa4-4d30-9c6e-c14ecb47d5a6
Version: 1
Effective date: 2025-12-18
Source export date: 2026-10-12
Source partition: 11
Source file: https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
Source object key: raw/openfda/drug-label/2026-10-12/a497e765d824a2e2aa9e88d5f0eea2aae9dcba363989e5f163395cda5c3c9dd8/drug-label-0011-of-0014.json.zip
Source manifest SHA-256: 7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
Import run: 20261013T011858Z
Imported at: 2026-10-13 02:43:11

Harmonized routes table
Harmonized routes
ORAL

Harmonized identifier links#

Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.

Harmonized identifiers page 1 of 1 · 15 matching rows.

Type, Scope, Identifier table
Type	Scope	Identifier	Source field
application applno	NDA	208019	derived:openfda.application_number
application number		NDA208019	openfda.application_number
brand name		POKONZA	openfda.brand_name
generic name		POTASSIUM CHLORIDE	openfda.generic_name
manufacturer name		Carwin Pharmaceutical Associates, LLC	openfda.manufacturer_name
ndc	package	15370-306-60	openfda.package_ndc
ndc	package	15370-306-30	openfda.package_ndc
ndc	product	15370-306	openfda.product_ndc
ndc11	package	15370030630	derived:openfda.package_ndc
ndc11	package	15370030660	derived:openfda.package_ndc
rxcui		2729280	openfda.rxcui
rxcui		2729282	openfda.rxcui
spl id		5e195343-8fa4-4d30-9c6e-c14ecb47d5a6	id
spl set id		0700c19e-abca-4527-8944-e4440a32e3af	set_id
unii		660YQ98I10	openfda.unii

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Gastrointestinal Irritation: Dilute before use, take with meals ( 5.1 ) 5.1 Gastrointestinal Irritation May cause gastrointestinal irritation. Increased dilution of the solution and taking with meals may reduce gastrointestinal irritation [see Dosage and Administration (2.1) ].

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. Most common adverse reactions are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Carwin Pharmaceutical Associates at 1-844-700-5011 or FDA at 1-800-FDA-1088 or www.fda.gov/ medwatch.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.